Scribd
Upload
68 views2 pages

Second Sight

Second Sight

Uploaded by

Masbooks
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd
68 views2 pages

Second Sight

Second Sight

Uploaded by

Masbooks
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd
You are on page 1/ 2

Second Sight Medical Products

Announces European Market Approval


of a Retinal Prosthesis for the Blind
Argus II Retinal Prosthesis System is the first such treatment for the blind
to obtain the CE Mark and make the leap from research to the marketplace.
Lausanne, March 2, 2011 - After more than 20 years of research and development involving a team of
international specialists, Second Sight Medical Products, Inc., the leading developer of retinal prostheses
for the blind, is pleased to announce that its Argus II Retinal Prosthesis System (Argus II) is now
approved for sale in the European Economic Area (EEA). After a successful clinical trial involving more
than 30 blind patients around the world, and a very thorough review of the products safety and
performance by an independent expert body, this device becomes the first approved treatment ever
available for sightless people.
After years of research, we are very happy to be able to offer a viable long-term solution for people
suffering from advanced retinal degenerative diseases such as retinitis pigmentosa (RP), said Robert
Greenberg, MD, President and CEO of Second Sight. The CE Mark approval, which comes after intense
regulatory review of our trial and our device, represents a huge step forward for the field and for these
patients who have, until now, had no proven treatment alternatives.
Argus II is Second Sights second generation implantable device intended to treat profoundly blind people
suffering from degenerative diseases such as RP. The system works by converting video images captured
from a miniature camera, housed in the patients glasses, into a series of small electrical pulses that are
transmitted wirelessly to an array of electrodes on the retina. These pulses then stimulate the retinas
remaining cells resulting in the corresponding perception of patterns of light in the brain. Patients learn to
interpret these visual patterns thereby gaining some functional vision. Thirty patients participated in the
clinical trial, using the device at home and in their daily lives since the trial started.
Although the resulting vision is far from normal, investigators in the clinical trial of the Argus II are excited
by the results. After more than 3 years of clinical trials, we were happy to demonstrate the performance,
safety and long-term reliability of Argus II, explained Professor Jos-Alain Sahel, Chairman, Department
of Ophthalmology: Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts, Paris, France. Adds Dr.
Lyndon da Cruz, MD PhD Consultant Retinal Surgeon at Moorfields Eye Hospital in London, UK The fact
that nearly all patients had a stable, safe and functioning system and that a majority of patients could
recognize large letters, locate the position of objects and the best could read short words impressed us
beyond our most optimistic expectations"
With this CE Mark approval, the Argus II is planned to be available later this year in the following clinical
centers: Centre Hospitalier National dOphthalmologie des Quinze-Vingts (Paris, France), Hpitaux
Universitaires de Genve (Geneva, Switzerland), Manchester Royal Eye Hospital (Manchester, UK), and
Moorfields Eye Hospital, (London, UK). Second Sight is actively adding sites to make the therapy more
readily available across the EEA in the coming months and years. The company is also focused on
obtaining insurance coverage for the device and surgical procedure.

This artificial retina brings hope to thousands of people with advanced retinal diseases added David
Head, Chief Executive of the British Retinitis Pigmentosa Society. The restoration of an element of vision
may bring with it the restoration of independence and mobility that would greatly improve a patients quality
of life.
Second Sight Medical Products, Inc., located in Los Angeles, California, was founded in 1998 to
create a retinal prosthesis to provide sight to patients blinded from outer retinal degenerations,
such as Retinitis Pigmentosa. Through dedication and innovation, Second Sight's mission is to
develop, manufacture and market implantable visual prosthetics to enable blind individuals to
achieve greater independence. Argus II is not yet approved for sale in the United States. European
Headquarters are in Lausanne, Switzerland.
For more information please contact
publicrelations@2-sight.com
+41 79 547 42 14
Information for patients:
patients@2-sight.com
+41 21 693 91 51

www.2-sight.com
Second Sight is a registered trademark and Argus is a trademark of Second Sight Medical Products, Inc.

You might also like

pFad - Phonifier reborn

Pfad - The Proxy pFad of © 2024 Garber Painting. All rights reserved.

Note: This service is not intended for secure transactions such as banking, social media, email, or purchasing. Use at your own risk. We assume no liability whatsoever for broken pages.


Alternative Proxies:

Alternative Proxy

pFad Proxy

pFad v3 Proxy

pFad v4 Proxy